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Abstract
Cardiovascular diseases are leading causes for death worldwide.
Genetic disposition jointly with traditional risk factors precipitates
their manifestation. Whereas the implications of a positive family
history for individual risk have been known for a long time, only in
the past few years have genome-wide association studies (GWAS)
shed light on the underlying genetic variations. Here, we review
these studies designed to increase our understanding of the patho-
physiology of cardiovascular diseases, particularly coronary artery
disease and myocardial infarction. We focus on the newly
established pathways to exemplify the translation from the identi-
fication of risk-related genetic variants to new preventive and
therapeutic strategies for cardiovascular disease.
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Introduction
Atherosclerosis is a systemic disorder with high prevalence in
both industrialized and developing countries. Its manifestations in
the form of cerebrovascular or coronary artery disease (CAD)
account for 46% of all deaths in Europe (Nichols et al, 2014).
Although progress in cardiovascular medicine has substantially
reduced the death toll in the past decades, deeper insight into the
pathophysiology of atherosclerosis is mandatory to further
improve strategies for the prevention and treatment. Epidemiolog-
ical studies, especially the Framingham Heart Study, spearheaded
the efforts to track down the causes for myocardial infarction
(MI) and led to the identification of several predictors for CAD,
for example hypertension and hypercholesterolaemia (Kannel
et al, 1961) which, together with obesity, smoking and diabetes,
are condensed under the term “modifiable risk factors”, as they
can be addressed by lifestyle changes and therapeutic interven-
tions (Yusuf et al, 2004).
It is also known that CAD has a high heritability that is by far
larger than the genetic influence on the modifiable risk factors
(Marenberg et al, 1994). However, for many decades, the attempts
to identify the genetic variants underlying this heritability were
unsuccessful (Mayer et al, 2007). Over the last few years, method-
ological progress and collaborative efforts have changed this
scenario. The invention of arrays for the low-cost genotyping of
hundreds of thousands of patient genomic markers, annotation of
these markers in the human genome together with meta-analyses
of multiple case–control samples have enabled the identification of
numerous genetic variants that are highly and reproducibly associ-
ated with CAD and MI risk.
Analysis of genotype frequencies with the aim to detect vari-
ants that occur at different frequency in cases and controls is
now being carried out at the genome-wide level. Variants found
in such genome-wide association studies (GWAS) to be associated
with disease risk are not necessarily located in the coding
regions. The fact that chromosomal loci tagged by respective vari-
ants do play a causal role in modulating risk is based on very
strong statistical significance; however, the mechanisms involved
remain often unclear. The hypothesis-free method of the GWAS
approach thereby differs from other emerging techniques such as
exome sequencing (Table 1), where specific genes are being
tested for association with disease. Moreover, the variant with
the strongest association in a GWAS does not necessarily repre-
sent the causal one; it may rather be in linkage disequilibrium
with a functionally relevant allele that is located in close proxim-
ity at this locus. Nevertheless, the GWAS approach has proven to
be a powerful tool: as discussed in this review, more than 50
single nucleotide polymorphisms (SNPs) tagging distinct chromo-
somal regions have been annotated so far to be associated with
CAD with high statistical significance. Here, we focus on variants
that allow inference to the causal genes and molecular pathways
and thus improve our understanding of the pathophysiology of
CAD and MI, which may ultimately result in better treatment and
prevention of these deadly diseases.
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Genome-wide association studies in coronary artery
disease and myocardial infarction
In 2007, the first GWAS were published for CAD, all of which identi-
fied a locus on chromosome 9p21 to be genome-wide significantly
associated with the disease (Helgadottir et al, 2007; McPherson
et al, 2007; Samani et al, 2007). This locus became the first claim of
what has later been called a gold rush of CAD genetics. Interest-
ingly, the chromosome 9p21 locus still has an outstanding position
as it depicts the genetic variant with the highest population-
attributable risk (Table 2; Schunkert et al, 2008).
In the first years of GWAS discoveries, identification of further
loci came from individual genome-wide association studies
(Erdmann et al, 2009; Myocardial Infarction Genetics Consortium
et al, 2009; Tregouet et al, 2009; IBC 50K CAD Consortium, 2011;
Wang et al, 2011), whereas more recently the formation of large,
international consortia has accumulated a sufficient statistical
power for new discoveries. The joint forces of the CARDIoGRAM
(Schunkert et al, 2011), C4D (Coronary Artery Disease C4D Genet-
ics Consortium, 2011) and finally the CARDIoGRAMplusC4D
(CARDIoGRAMplusC4D Consortium et al, 2013; Nikpay et al,
2015) consortium allowed the analysis of up to 180,000 indivi-
duals, about half of which had CAD. Interestingly, consequent
studies revealed a strong relationship between the numbers of
individuals investigated and the numbers of genome-wide signifi-
cant variants detected by the GWAS approach (Fig 1). This close
correlation makes it likely that many more variants may eventually
achieve genome-wide significant association once even larger
sample sets will be studied.
Another means to increase the power of GWAS is by denser
granularity of SNPs. This progress was initially driven by better
arrays allowing the genotyping of more and more SNPs. More
recently, improvement came from imputation of SNPs based on
the 1,000 genomes sequencing data set (1000 Genomes Project
Consortium et al, 2012). It is now possible to study more than
15 Mio. distinct SNPs in human DNA for association with
disease. Denser genotyping and higher numbers of study subjects
increased the number of loci with genome-wide significant asso-
ciation for CAD to 56 (CARDIoGRAMplusC4D Nikpay et al,
2015). Table 2 gives an overview about the loci thus far identi-
fied to be genome-wide significantly associated with CAD by
GWAS.
Almost all risk variants identified by GWAS are commonly
found in European populations. This led to the unexpected
finding that an average European individual carries tens of these
risk alleles. Moreover, almost all are located in non-coding parts
of the genome, which suggests that these variants are more
likely to affect gene regulation rather than protein structure.
Indeed, annotation of the risk alleles revealed that the majority
are located in chromosomal regions relevant for gene regulation.
The identification of the underlying pathophysiological mecha-
nism(s) thus requires annotation of the affected gene(s), which
may be challenging (Braenne et al, 2015). The chromosome
9p21 locus is a prominent example: whereas initial studies
focused on the two genes situated at the locus, CDKN2A and
CDKN2B, current studies rather point to radically new disease
mechanisms. Indeed, it appears that the risk/non-risk alleles at
the 9p21 locus relate to different isoforms of ANRIL and subse-
quently to preferred synthesis of non-circular/circular forms of
this long non-coding RNA, which affect via ribosomal function
the expression of multiple genes leading ultimately to opposing
effects on cell proliferation and apoptosis (Holdt et al, 2010,
2013).
Exome-wide association study in coronary artery disease
The annotation to a gene is easier to achieve if the SNP leading a
GWAS signal causes a mutation in the coding region presumably
influencing protein function (Table 3). Important examples that will
Glossary
Coronary artery disease
Coronary artery disease is the manifestation of atherosclerosis in the
coronary arteries, that is the vessels supplying the myocardium with
oxygen and nutrients. Major complications of coronary artery disease
include chest pain, myocardial infarction, arrhythmias and heart
failure. It is one of the leading causes of death.
Extracellular matrix
The extracellular matrix is a conglomerate of molecules and cells of
often different types. The fibroblasts are the main cell type involved in
the formation of the extracellular matrix. In addition to the effects on
tissue/organ physical properties, for example elasticity and stiffness,
the extracellular matrix also has effects on the behaviour of imbedded
cells, that is migration but also gene expression and differentiation.
Linkage disequilibrium
Linkage disequilibrium describes the occurrence that two alleles at
different loci are not independently distributed in a population.
Precision medicine
The response to a treatment modality may vary, even in patients with
the same diagnosis. Precision medicine aims to tailor healthcare to
individual patients. It can involve molecular diagnostics but also
laboratory tests, imaging, environmental analyses and large-scale data
analysis, for example pattern recognition.
Single Nucleotide Polymorphisms
Single nucleotide polymorphisms (SNPs) are variations in
single nucleotides that occur in the genome with distinct
frequencies. Association studies exploit the analysis of SNPs to
investigate the association of these genetic variants with a
particular disease.
Statins
Statins are drugs used to lower lipid levels, especially
low-density lipid (LDL) cholesterol. The molecular target of
statins is the enzyme HMG-CoA reductase, a key player in the
endogenous production of cholesterol. Statins have proven
efficacy in the reduction in both LDL cholesterol and
cardiovascular events.
Systems medicine
Systems medicine is a novel discipline in biomedical
research, closely related to systems biology. Systems medicine
aims to study the individual in an integrated fashion,
incorporating, for example, “-omics” data, and biochemical and
environmental interactions. As a further dimension, changes
over time are included in the analyses. A major focus in
systems medicine research is the development of computational
models.
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be discussed in more detail below include the PCSK9 and GUCY1A3
genes. Therefore, the idea arose to systematically investigate coding
variants.
The results of the first exome-wide association study on CAD
have been just published (Stitziel et al, 2016). The authors included
more than 72,000 cases and more than 120,000 controls, respec-
tively. They confirmed signals in the LPA and PCSK9 genes but also
identified novel variants in genes thus far not associated with CAD:
a missense variant in the ANGPTL4 gene and a missense variant in
the sushi, von Willebrand factor type A, EGF and pentraxin domain
containing 1 gene (SVEP1). SVEP1 was not associated with lipid
levels, but with both systolic and diastolic blood pressure leading to
an increase of 0.94 and 0.57 mmHg, respectively, in those carrying
the risk allele (Stitziel et al, 2016). Moreover, SVEP1 has been
investigated in septic shock and endotoxaemia (Nakada et al, 2015).
Specifically, the inhibition of SVEP1 expression by RNAi was found
to regulate the expression of adhesion molecules on the surface of
endothelial cells (Schwanzer-Pfeiffer et al, 2010). One paper also
identified SVEP1 as the physiological ligand of integrin a9b1. Inte-
grins are key molecules in the interaction of different cell types
through the extracellular matrix (ECM) such that it may be feasible
that SVEP1 influences cell adhesion mediated by integrin a9b1
(Sato-Nishiuchi et al, 2012), which could be of pathophysiological
relevance in CAD.
Pathophysiological insights
Bioinformatics analyses and experimental studies revealed the
involvement of the genes affected by risk alleles in different patho-
physiological pathways (Figs 2 and 3). In the following paragraphs,
we highlight the effects on LDL cholesterol and triglyceride metabo-
lism, blood pressure, NO/cGMP signalling, vascular remodelling
and inflammation.
LDL cholesterol metabolism
Of the 56 loci identified so far, a number affect lipid metabolism as
an intermediary step, for example the LDL cholesterol receptor
(LDLR) or LPA loci (Table 2). Interestingly, some of the genes found
to associate with hypercholesterolaemia and CAD had never been
implicated in these disorders before. Consequently, the novel loci
suggest unexpected mechanisms affecting lipid metabolism. A
prominent example is sortilin 1, encoded by the SORT1 locus on
chromosome 1 (Samani et al, 2007; Musunuru et al, 2010). Another
example is PCSK9, which is discussed in more detail below because
of the striking therapeutic options (Fig 3A).
Triglyceride metabolism
Lipoprotein lipase (LPL), also genome-wide significantly associated
with CAD, seems to be a key player in CAD genetics, too. Under
physiological conditions, LPL reduces triglyceride levels via the
hydrolysis of lipoprotein-bound triglycerides. LPL activity is
increased by apolipoprotein A-V (APOA5), but reduced by
apolipoprotein C-III (APOC3) and angiopoietin-like 4 (ANGPTL4),
all of which have been associated with CAD in a genome-wide signif-
icant fashion (Table 3). It has been mentioned above that the
ANGPTL4 gene has just recently been identified in an exome-wide
association study to be associated with CAD. Indeed, the protective
allele p.E40K represents a loss-of-function variant. Our consortium
was able to demonstrate that this and other loss-of-function variants
led to significantly reduced triglyceride levels, whereas LDL and
HDL cholesterol levels were not affected. In accordance, loss-of-
function variants were associated with a lower risk for CAD. This
becomes even more apparent since we also detected a missense
variant in the LPL gene, which led to a 20% reduction in LPL activ-
ity, to be associated with increased risk for CAD (Stitziel et al,
2016). The findings for LPL and ANGPTL4 confirm recent results for
two other regulators of LPL activity, APOA5 and APOC3, in that rare
APOA5 mutations increase both plasma triglyceride levels and risk
of CAD (Do et al, 2015), whereas rare loss-of-function mutations in
the APOC3 gene have opposite effects (The TG and HDL Working
Group of the Exome Sequencing Project, National Heart, Lung, and
Blood Institute, 2014). Taken together, LPL activity seems to have a
central role in triglyceride metabolism (Fig 3A) and consecutively
CAD risk (Fig 4). Therefore, these proteins could represent possible
targets for therapeutic intervention. Accordingly, attention should
be paid to ongoing studies regarding APOC3 inhibitors, which are
discussed in more detail below.
Blood pressure
Thanks to extensive genotyping efforts, several genomic loci have
been identified to be associated with blood pressure. A score build
on the cumulative effects of these loci displays a strong associa-
tion with CAD (Levy et al, 2009; Newton-Cheh et al, 2009;
Table 1. Association approaches in cardiovascular research (*) can be grouped into haplotypes, which may allow to derive more genetic
information or imputation of other SNPs; #, can be further categorized if functional implications are known, for example effect of expression
level = eSNP; +; may vary in different tissues or conditions.
GWAS EWAS Exome array Exome sequencing Genome sequencing
Focus Common SNPs*# CpG methylation
sites
Exonic variants Coding sequences of
all genes (high coverage)
Sequences of all genes
(high coverage)
N of signals ~8106 ~500103 ~220103 ~30106 3109
Coverage Whole genome Whole genome+ All genes All genes Whole genome
Costs per
person [$]
~100 ~300 ~100 ~600 > 1,000
bp, base pairs; EWAS, epigenome-wide association study; GWAS, genome-wide association study; N, number.
EMBO Molecular Medicine Vol 8 | No 7 | 2016 ª 2016 The Authors
EMBO Molecular Medicine GWAS in cardiovascular disease Thorsten Kessler et al
690
Table 2. Loci identified to be associated with CAD/MI either by genome-/exome-wide association studies.
Chr. Lead SNP AF OR
Gene at chr.
locus Bioinf. annot. HTN LIP References
1 rs11206510 T (0.82) 1.08 PCSK9 No data + Myocardial Infarction Genetics
Consortium (2009), Abifadel et al (2003),
Cohen et al (2006), Teslovich et al (2010)
rs17114036 A (0.91) 1.17 PPAP2B No data Schunkert et al (2011)
rs17465637 C (0.74) 1.14 MIA3 MIA3, AIDA, C1orf58 Samani et al (2007), Schunkert et al (2011)
rs599839 A (0.78) 1.11 SORT1 SORT1 + Schunkert et al (2011), Teslovich et al
(2010), Samani et al (2007)
rs4845625 T (0.47) 1.06 IL6R IL6R, ATP8B2,
CHTOP, UBAP2L
CARDIoGRAMplusC4D Consortium (2013)
2 rs6544713 T (0.30) 1.06 ABCG5/ABCG8 No data + Schunkert et al (2011), Teslovich et al
(2010), IBC 50K CAD Consortium (2011)
rs6725887 C (0.15) 1.14 WDR12 NA Schunkert et al (2011), Myocardial
Infarction Genetics Consortium (2009)
rs515135 G (0.83) 1.07 APOB No data + CARDIoGRAMplusC4D Consortium (2013),
Teslovich et al (2010)
rs2252641 G (0.46) 1.06 ZEB2 No data CARDIoGRAMplusC4D Consortium (2013)
rs1561198 A (0.45) 1.06 VAMP5-VAMP8-GGCX VAMP5/8 CARDIoGRAMplusC4D Consortium (2013)
3 rs2306374 C (0.18) 1.12 MRAS MRAS, CEP70 Erdmann et al (2009), Schunkert et al (2011)
4 rs7692387 G (0.81) 1.08 GUCY1A3 no data + CARDIoGRAMplusC4D Consortium (2013),
Erdmann et al (2013), International
Consortium for Blood Pressure Genome-
Wide Association Studies (2011)
rs1878406 T (0.15) 1.10 EDNRA NA CARDIoGRAMplusC4D Consortium (2013)
rs17087335 T (0.21) 1.06 REST-NOA1 NA Nikpay et al (2015)
5 rs2706399 G (0.51) 1.07 IL5 NA IBC 50K CAD Consortium (2011)
rs273909 C (0.14) 1.07 SLC22A4-A5 No data CARDIoGRAMplusC4D Consortium (2013)
6 rs12526453 C (0.67) 1.10 PHACTR1 No data Schunkert et al (2011), Myocardial
Infarction Genetics Consortium (2009)
rs17609940 G (0.75) 1.07 ANKS1A NA Schunkert et al (2011)
rs12190287 C (0.62) 1.08 TCF21 No data Schunkert et al (2011)
rs3798220 C (0.02) 1.51 LPA, SLC22A3, LPAL2 LPA + Tregouet et al (2009), Schunkert et al
(2011), Teslovich et al (2010)
rs10947789 T (0.76) 1.07 KCNK5 No data CARDIoGRAMplusC4D Consortium (2013)
rs4252120 T (0.73) 1.07 PLG PLG, LPAL2 CARDIoGRAMplusC4D Consortium (2013)
7 rs10953541 C (0.80) 1.08 BCAP29 No data Coronary Artery Disease C4D Genetics
Consortium (2011)
rs11556924 C (0.62) 1.09 ZC3HC1 ZC3HC1 Schunkert et al (2011)
rs2023938 G (0.10) 1.08 HDAC9 No data CARDIoGRAMplusC4D Consortium (2013)
rs3918226 T (0.06) 1.14 NOS3 NOS3 Nikpay et al (2015)
8 rs2954029 A (0.55) 1.06 TRIB1 No data + IBC 50K CAD Consortium (2011),
CARDIoGRAMplusC4D Consortium (2013),
Teslovich et al (2010)
rs264 G (0.86) 1.11 LPL LPL + CARDIoGRAMplusC4D Consortium (2013),
Teslovich et al (2010), Stitziel et al (2016)
9 rs4977574 G (0.46) 1.29 9p21.3 ANRIL Samani et al (2007), McPherson et al
(2007), Helgadottir et al (2007), Schunkert
et al (2011), Holdt et al (2010)
rs579459 C (0.21) 1.10 ABO NA + Schunkert et al (2011), Teslovich et al
(2010), Reilly et al (2011)
rs111245230 C (0.04) 1.14 SVEP1 NA Stitziel et al (2016)
ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 7 | 2016
Thorsten Kessler et al GWAS in cardiovascular disease EMBO Molecular Medicine
691
Table 2 (continued)
Chr. Lead SNP AF OR
Gene at chr.
locus Bioinf. annot. HTN LIP References
10 rs2505083 C (0.38) 1.07 KIAA1462 KIAA1462 Erdmann et al (2009), Coronary Artery
Disease C4D Genetics Consortium (2011)
rs1746048 C (0.87) 1.09 CXCL12 NA Samani et al (2007), Schunkert et al
(2011)
rs1412444 T (0.42) 1.09 LIPA NA Coronary Artery Disease C4D Genetics
Consortium (2011)
rs12413409 G (0.89) 1.12 CYP17A1, NT5C2 NA + Schunkert et al (2011), Newton-Cheh et al
(2009), Levy et al (2009)
11 rs974819 T (0.32) 1.07 PDGFD No data Coronary Artery Disease C4D Genetics
Consortium (2011)
rs964184 G (0.13) 1.13 APOA1-C3-A4-A5 No data + Schunkert et al (2011), The TG and HDL
Working Group of the Exome Sequencing
Project, National Heart, Lung, and Blood
Institute (2014), Do et al (2015, 2013)
12 rs10840293 A (0.55) 1.06 SWAP70 NA Nikpay et al (2015)
rs3184504 T (0.44) 1.07 SH2B3, HNF1A SH2B3, FLJ21127,
ATXN2
+ + Schunkert et al (2011), Teslovich et al
(2010), Newton-Cheh et al (2009), Levy
et al (2009), Gudbjartsson et al (2009)
rs11830157 G (0.36) 1.12 KSR2 NA Nikpay et al (2015)
13 rs4773144 G (0.44) 1.07 COL4A1, COL4A2 No data Schunkert et al (2011)
rs9319428 A (0.32) 1.06 FLT1 No data CARDIoGRAMplusC4D Consortium (2013)
14 rs2895811 C (0.43) 1.07 HHIPL1 YY1 Schunkert et al (2011)
15 rs3825807 A (0.57) 1.08 ADAMTS7 ADAMTS7 Schunkert et al (2011), Reilly et al (2011),
Coronary Artery Disease C4D Genetics
Consortium (2011)
rs17514846 A (0.44) 1.07 FURIN-FES FURIN, MAN2A2 + CARDIoGRAMplusC4D Consortium (2013),
International Consortium for Blood
Pressure Genome-Wide Association
Studies (2011)
rs56062135 C (0.79) 1.07 SMAD3 NA Nikpay et al (2015)
rs8042271 G (0.9) 1.10 MFGE8-ABHD2 NA Nikpay et al (2015)
17 rs216172 C (0.37) 1.07 SMG6-SRR NA Schunkert et al (2011)
rs12936587 G (0.56) 1.07 PEMT, RASD1, SMCR3 TOM1L2 Schunkert et al (2011)
rs46522 T (0.53) 1.06 UBE2Z, GIP, ATP5G1 NA Schunkert et al (2011)
rs7212798 C (0.15) 1.08 BCAS3 NA Nikpay et al (2015)
18 rs663129 A (0.26) 1.06 PMAIP1-MC4R NA Nikpay et al (2015)
19 rs116843064 G (0.98) 1.14 ANGTPL4 NA + Teslovich et al (2010), Stitziel et al (2016)
rs1122608 G (0.77) 1.14 LDLR SMARCA4 + Myocardial Infarction Genetics
Consortium (2009), Schunkert et al (2011),
Teslovich et al (2010), Do et al (2015)
rs2075650 G (0.14) 1.14 APOE TOMM40 + IBC 50K CAD Consortium (2011), Teslovich
et al (2010)
rs12976411 A (0.91) 1.33 ZNF507- LOC400684 NA Nikpay et al (2015)
21 rs9982601 T (0.15) 1.18 MRPS6, SLC5A3, KCNE2 No data Myocardial Infarction Genetics
Consortium (2009)
22 rs180803 G (0.97) 1.20 POM121L9P-ADORA2A NA Nikpay et al (2015)
Chr., chromosome/chromosomal; SNP, single nucleotide polymorphism; AF, risk allele and its frequency; OR, odds ratio; HTN, associated with blood pressure; LIP,
associated with LDL cholesterol/lipoprotein (a)/triglycerides; Bioinf. annot., bioinformatics annotation according to Braenne et al (2015) or others (Musunuru et al,
2010; Salvi et al, 2013); no data, no eQTL data or non-coding variant; NA, not analysed.
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International Consortium for Blood Pressure Genome-Wide Associ-
ation Studies et al, 2011). Among the loci identified, there are
several which are also genome-wide significantly associated with
CAD (Table 2, Fig 3B). It remains, however, unclear to which
extent the effect on CAD is due to an increase in blood pressure
given that the effect on blood pressure for each locus is very
small (Lieb et al, 2013).
NO/cGMP signalling
Nitric oxide (NO) is an important signalling molecule (Fig 3C) in the
cardiovascular system, and the expression of endothelial NO
synthase (eNOS), which produces NO from arginine, is reduced in
atherosclerosis (Kawashima, 2004). As NO inhibits proatherogenic
mechanisms such as platelet aggregation, smooth muscle cell prolif-
eration/migration and adhesion of inflammatory cells (Davignon,
2004), it is plausible that a lack of NO itself is deleterious in the
context of atherosclerosis. Furthermore, uncoupling of eNOS, for
example when levels of the NO precursor arginine are reduced, may
produce reactive oxygen species instead of NO, further promoting
atherosclerosis (Kawashima, 2004). Interestingly, the NOS3 gene
has just recently been identified to be associated with CAD (Nikpay
et al, 2015). Additionally, there is evidence that the particular vari-
ant (rs3918226), which is located in the promoter of the NOS3 gene,
influences the expression of eNOS with a negative effect of the risk
allele (Salvi et al, 2013). As briefly discussed above, the NOS3 gene
has also been associated with blood pressure (Salvi et al, 2012,
2013). Bearing in mind that NO leads to vasodilatation, this is plau-
sible. The effects on CAD risk are, however, larger than one would
expect if just being mediated via increased blood pressure.
The major NO receptor, soluble guanylyl cyclase (sGC), also
seems to play a role in the genetics of CAD. Indeed, the a1-subunit
(GUCY1A3) of sGC was shown by the meta-analysis of the CARDIo-
GRAMplusC4D consortium to harbour a common variant associated
with CAD (CARDIoGRAMplusC4D Consortium et al, 2013).
However, even more evidence comes from the detection of a rare
loss-of-function variant identified in an extended family with high
prevalence of premature CAD and MI (Erdmann et al, 2013), in
which exome sequencing identified a digenic mutation in GUCY1A3
and CCT7 to be responsible for the phenotype. Furthermore, mice
lacking the a1-subunit of the sGC have been shown to display accel-
erated thrombus formation (Erdmann et al, 2013). Platelets indeed
play an important role not only in atherothrombosis but also in
atherosclerosis (Von Hundelshausen & Weber, 2007). Studies inves-
tigating the effect of sGC on plaque formation in mouse models are
eagerly awaited. A protective role of sGC is thereby strongly
suggested by studies showing that cGMP formation is reduced in
neointimal lesions (Melichar et al, 2004) and that cGMP leads to
down-regulation of the expression of adhesion molecules for the
recruitment of leucocytes into atherosclerotic plaques (Ahluwalia
et al, 2004). The common variant associated with CAD (rs7692387)
is located in an intron however, and the exact mechanism from
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Figure 1. Numbers of individuals and SNPs investigated by GWAS influence the power for the detection of associated loci.
The number of investigated individuals in the discovery phases of the relative GWAS/meta-analyses was plotted against the number of variants reaching genome-wide level of
significance in the overall analysis of the studies. Association between individuals in the discovery phase and the number of hits was evaluated by linear regression. P < 0.05
was considered as statistically significant. GraphPad Prism version 6.0c for Mac OS X (GraphPad Software, La Jolla, CA, USA) was used. (A) The number of SNPs detected at
genome-wide significant level for coronary artery disease in consecutive studies. (B) The number of SNPs detected with genome-wide significance after replication correlates
with the number of individuals included in the discovery studies. Symbols denote the numbers of genotyped SNPs [dots: ≤ 500,000 SNPs (Samani et al, 2007; McPherson et al,
2007; Helgadottir et al, 2007; Myocardial Infarction Genetics Consortium, 2009; Erdmann et al, 2009; Tregouet et al, 2009; IBC 50K CAD Consortium, 2011; Lu et al, 2012);
asterisks: 2,500,000 SNPs (Coronary Artery Disease C4D Genetics Consortium, 2011; Schunkert et al, 2011; CARDIoGRAMplusC4D Consortium et al, 2013); arrow: 940,000 SNPs
(Nikpay et al, 2015)].
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NOS3, the GUCY1A3 gene is also associated with blood pressure
(International Consortium for Blood Pressure Genome-Wide Associ-
ation Studies et al, 2011).
Vascular remodelling
Arterial remodelling is a crucial process in atherosclerosis (Fig 3D).
Interestingly, constrictive remodelling and expansive remodelling
of arteries exhibit different plaque morphologies: constrictive
remodelling accompanied by lumen narrowing presents with more
stable plaques, whereas expansive remodelling does not feature
lumen narrowing but is associated with rather unstable plaques
(Pasterkamp et al, 1998; Smits et al, 1999). A novel mechanism link-
ing these observations might involve ADAMTS-7, an extracellular
matrix (ECM) protease. Variants in ADAMTS7 have been identified
to be associated with CAD (Coronary Artery Disease C4D Genetics
Consortium, 2011; Reilly et al, 2011; Schunkert et al, 2011).
ADAMTS7 was more strongly associated with CAD rather than MI,
suggesting a major role in plaque formation and not in plaque
rupture (Reilly et al, 2011). At that time, little was known about
ADAMTS7 in cardiovascular diseases. One study had shown that the
expression of the rat counterpart Adamts-7 is found to be increased
in carotid arteries secondary to balloon injury (Wang et al, 2009).
This effect was supposed to lead to the degradation of an abundantly
expressed ECM protein, cartilage oligomeric matrix protein (COMP).
COMP itself had been shown to affect vascular smooth muscle cells
with intact COMP maintaining a differentiated, contractile phenotype
(Wang et al, 2010). In the meantime, two studies investigating the
role of ADAMTS7 in mouse models revealed evidence that mice lack-
ing Adamts-7 (Adamts7/) display reduced atherosclerotic plaque
formation compared to WT littermates when they are on a
proatherogenic background and fed a western diet. This effect was
most prominent in Adamts7/Ldlr/ mice with a strong reduction
in plaque formation in the aortic root as well as in the en face whole
aorta analysis (Bauer et al, 2015). The mechanism underlying this
phenotype is still unclear. The second study focused on vascular
remodelling. Adamts7/ mice displayed strongly reduced neoin-
tima formation after wire-mediated vascular injury (Bauer et al,
2015; Kessler et al, 2015), a phenotype that is supposed to be mainly
mediated by beneficial effects in endothelial cells (Kessler et al,
2015). Endothelial cells of Adamts7/ mice showed increased
proliferation and migration in vitro. In accordance, reendothelial-
ization of injured arteries was significantly accelerated in
Adamts7/ compared to WT mice. This effect is thought to be due
to the inhibition of the degradation of a novel ADAMTS-7 target—
thrombospondin-1 (TSP-1)—into bioactive fragments (Kessler et al,
2015). The concept of cell–matrix and ECM-mediated cell–cell
communication via finely regulated expression of proteases is attrac-
tive, especially regarding ECM proteins that contain several domains
with differential functions such as TSP-1 (Iruela-Arispe et al, 1999).
Interestingly, TSP1 has also been investigated in candidate gene
studies in CAD (Stenina et al, 2007). As for many other candidates
that have been investigated in the pre-GWAS era, for example the
ACE gene (Mayer et al, 2007), no signal has been detected for the
TSP1 gene in GWAS so far.
Inflammation
Inflammation is a central feature of atherosclerosis (Fig 3E)
(Swirski & Nahrendorf, 2013). This also holds true for its genetic
component. Indeed, the genes encoding the cytokine CXCL12 and
the interleukin 6 receptor (IL6) have been associated with CAD. In
line, a pathway analysis of the CARDIoGRAMplusC4D meta-
analysis has also shown a major role for variants in inflammatory
genes (CARDIoGRAMplusC4D Consortium, 2013). By contrast,
C-reactive protein (CRP) appears to be rather a marker than a
Table 3. Genes associated with CAD/MI with lead SNPs, or proxy SNPs
of the respective lead SNP, causing a deleterious variation, and genes






1 CCDC181 p.F238I ↑ Braenne et al (2015)





Abifadel et al (2003)
Cohen et al (2006)
2 WDR12 p.I75V ↑ Braenne et al (2015)
TNS1 p.W1197R ↑ Braenne et al (2015)
3 MAP4 p.V628L/p.S427Y ↑ Braenne et al (2015)
4 GUCY1A3 Nonsense/
p.Gly537Arg
↑ Erdmann et al (2013)













Stitziel et al (2016)
9 SVEP1 p.D2702G ↑ Stitziel et al (2016)
10 BMPR1A p.P2T ↑ Braenne et al (2015)
11 APOA5 Non-synonymous ↑ Do et al (2015)
APOC3 Non-synonymous/
splice site/null







12 HNF1A p.I27L ↑ Braenne et al (2015)




↑ Do et al (2015)
ANGPTL4 p.E40K ↓ Stitziel et al (2016)
20 MYH7B p.A25T ↑ Braenne et al (2015)
PROCR p.S219G ↑ Braenne et al (2015)
Chr., chromosome; AA, amino acid; ↑, variant increases risk; ↓, variant
decreases risk.
See also Table 1 and Fig 3.
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causal factor, as its genetic variation does not translate to CAD risk
(Schunkert & Samani, 2008; Zacho et al, 2008; Elliott et al, 2009;
C Reactive Protein Coronary Heart Disease Genetics Collaboration
(CCGC) (2011)).
Novel insights might come from functional investigation of the
SH2B3/LNK gene. The variant rs3184504 tagging the SH2B3 gene is
associated with CAD (Gudbjartsson et al, 2009; CARDIoGRAM-
plusC4D Consortium, 2013). The interpretation of this association is
complicated by the fact that this particular variant also represents
an eSNP for a neighbour gene, ATXN2 (Braenne et al, 2015). Never-
theless, the SH2B3 gene, which encodes an adaptor protein
expressed, for example, in leucocytes and platelets, revealed in a
knock-out mouse model (Lnk/) increased platelet counts, but
reduced thrombus stability (Takizawa et al, 2010). Bearing in mind
that the risk allele at the SH2B3 locus is also associated with
increased platelet count (Soranzo et al, 2009), altered Sh2b3/Lnk
function—as present in the mouse—seems to be a suitable model to
analyse the functional impact of the variant in CAD. Besides the
platelet phenotypes (Soranzo et al, 2009; Takizawa et al, 2010) and
the also known association with blood pressure (Levy et al, 2009;
Newton-Cheh et al, 2009), SH2B3 seems to mainly influence
inflammatory processes. From a genetic point of view, this is
already noticeable from the associations of the locus with different
inflammatory diseases, for example coeliac disease (Hunt et al,
2008), type 1 diabetes (Barrett et al, 2009; Concannon et al, 2009)
and high eosinophil numbers (Gudbjartsson et al, 2009). An experi-
mental study revealed that Sh2b3/Lnk influences the activation of
dendritic cells, thereby modulating the immune response, that is
dendritic cells from Lnk/ mice are hyper-responsive to IL-15,
resulting in an excessive production of IFN-c (Mori et al, 2014). So
far, the results regarding atherosclerotic phenotypes are still lacking.


















































































Figure 2. Genetic variation and pathophysiological pathways in atherosclerosis.
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Figure 3. Genes involved in different pathophysiological pathways extracted from the 56 loci listed in Table 2.
Functional annotations were collected from (i) the ConsensusPathDB database (http://consensuspathdb.org; Kamburov et al, 2013), (ii) the AmiGO 2 Gene Ontology (GO)
browser (http://amigo.geneontology.org/amigo; Carbon et al, 2009), as well from (iii) the biomedical literature. Known and predicted associations among the genes within
each functional category/pathway were retrieved from the STRING database (http://string-db.org; Franceschini et al, 2013) using default parameters. (A) Lipid metabolism.
(B) Blood pressure. (C) NO-cGMP signalling/platelet aggregation. (D) Vascular remodelling. (E) Inflammation.
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Sh2b3/Lnk led to significantly increased fibrosis and leucocyte infil-
tration, resulting in reduced cardiac function (Flister et al, 2015).
Taken together, genetic and experimental results point to a role for
SH2B3/LNK in inflammatory processes in CAD, making SH2B3/LNK
a promising candidate for therapeutic interventions.
Therapeutic strategies
One major aim of the efforts to elucidate the genetic basis of CAD
and MI is the identification of novel targets and the consequent
development of novel strategies in prevention and therapy. Of
interest, targets identified by genetic studies are estimated to be
twice as successful in the development of new drugs compared to
those identified by other means (Barrett et al, 2015; Nelson et al,
2015).
As discussed above, some genetic variants influence traditional
risk factors, such as blood pressure and lipid metabolism, which
may be targets for treatment themselves. In addition, based on
genetic discoveries, targeted novel therapies may become available
for focussed interference with lipid metabolism or currently unex-
ploited mechanisms.
Novel therapeutics in lipid metabolism
LPA, PCSK9, LPL, ANGPTL4, APOA5 and APOC3 are several
promising targets in lipid metabolism available for therapeutic inter-
ference (Fig 4). PCSK9 is the most established one, since it has been
known for more than a decade that gain-of-function and loss-of-
function variants in the PCSK9 gene increase (Abifadel et al, 2003)
and decrease (Cohen et al, 2006) the risk of CAD and MI, respec-
tively. GWAS also identified an association between common vari-
ants in the PCSK9 gene and both cholesterol levels (Teslovich et al,
2010) and CAD (Myocardial Infarction Genetics Consortium et al,
2009). PCSK9 functions in LDL cholesterol metabolism by tagging
for the degradation of intracellular as well as extracellular LDL









Figure 4. Novel insights into the genetic variation in LDL cholesterol metabolism and therapeutic modulation.
In low-density lipoprotein (LDL) metabolism, sortilin 1 (SORT1), LDL cholesterol receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) are exemplarily
shown (green, favourable effect regarding LDL cholesterol/triglycerides; red, unfavourable effect regarding LDL cholesterol/triglycerides; ↑, variants increase the risk of CAD;
↓, variants decrease the risk of CAD).
Table 4. Currently investigated PCSK9 inhibitors.
Name Mechanism of action Phase of development Approved LDL
Evolocumaba Human mAb Phase IV Yese ↓ 61% (Sabatine et al, 2015)
Alirocumabb Human mAb Phase IV ↓ 62% (Robinson et al, 2015)
Bococizumabc Humanized mAb (Liang et al, 2012) Phase II No ↓ 21–54% (Ballantyne et al, 2015)
ALN-PCSd Antisense oligo (Frank-Kamenetsky et al, 2008) Phase I No ↓ 40% (Fitzgerald et al, 2014)
NA VLP-based vaccine (Crossey et al, 2015) Preclinical No NA




dAlnylam, The Medicines Company.
eApproved for familial hypercholesterolaemia, statin intolerance and insufficient LDL cholesterol control with statins.
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therapeutic concepts exploit monoclonal antibodies to inhibit the
effect of PCSK9 in the circulation but also RNAi- and small mole-
cule-based approaches are in the development and evaluation.
Table 4 provides an overview over the compounds currently under
investigation using PCSK9 as target.
LPL and the proteins regulating its activity are also attractive
targets for novel treatment strategies. As discussed above, APOC3
reduces LPL activity. Accordingly, inhibition of APOC3 by RNAi-
mediated knockdown is currently being investigated in clinical
trials. In a dose-ranging phase II study, ISIS 304801, an antisense
APOC3 inhibitor, led to a dose-dependent 31–71% reduction in
triglycerides (Gaudet et al, 2015). Also ANGPTL4, a gene recently
identified by an exome-wide association study and also involved in
the regulation of LPL activity, may be the target of novel drug
approaches: mice deficient for Angptl4 display reduced triglyceride
levels mainly due to increased clearance and reduced production of
very low-density lipoproteins (Desai et al, 2007).
Targeting NO/cGMP signalling
The NO/cGMP pathway appears to play an important role in
atherosclerosis since two key enzymes, that is eNOS and sGC, are
genome-wide significantly associated with CAD (CARDIoGRAM-
plusC4D Consortium, 2013; Nikpay et al, 2015). Additionally, the
importance of the pathway has been confirmed by the fact that loss-
of-function mutations affecting the function of the sGC are responsi-
ble for premature CAD and MI in an extended family (Erdmann et al,
2013). Whereas the mechanism involving the common variants
remains to be elucidated, several therapeutic options are already
available. Although increasing the availability of NO might not be
achieved the expected success due to adverse effects and pharma-
cokinetic obstacles, targeting the sGC directly could solve these prob-
lems at least in part. Riociguat is a sGC stimulator already in clinical
use. In the PATENT trial, the drug has proven efficacy in patients
with pulmonary hypertension (Ghofrani et al, 2013). Riociguat is
also very interesting because it acts synergistically with NO (Stasch
& Hobbs, 2009); that is, reduced sGC activity or expression could
hypothetically be compensated by the presence of such modulators
of sGC activity. Future experimental studies are needed to explore
the effect of sGC stimulators on atherosclerosis phenotypes.
Precision medicine
One possibility of improving treatment is the identification and eval-
uation of novel drug targets. A second way to exploit GWAS
findings is to develop individualized treatment strategies. The devel-
opment of so-called precision medicine is a major goal of current
funding concepts (Jameson & Longo, 2015). Unfortunately, there is
currently only limited evidence to suggest that genetic testing of
individual common risk variants allows for stratification into dif-
ferent treatment modalities. However, individuals with a high
genetic risk score appear to have a larger benefit from statin treat-
ment than those with low genetic risk (Hughes et al, 2012; Mega
et al, 2015; Schunkert & Samani, 2015). Further, stimulating input
in this field might come from systems medicine approaches
(Bjoerkegren et al, 2015). For example, an integrative analysis
revealed an enrichment of CAD-associated variants in differentially
co-expressed microRNA–mRNA pairs (Huan et al, 2013).
Outlook
GWAS have led to the identification of more than 50 genetic vari-
ants associated with CAD and MI so far, and likely more will follow.
These variants reflect an important progress in defining the mecha-
nisms leading to disease. However, the variants identified thus far
only account for no more than 10% of the heritable risk. Future
studies will aim to detect rare variants with strong impact on disease
risk and might thus close this gap. Additionally, the field of epista-
sis, that is the interaction of different genes, is rapidly evolving.
Finally, it has been shown for other complex disorders that the
combined small effects of hundreds of thousands of SNPs may
jointly explain the currently poorly understood inheritance patterns
(Yang et al, 2015). The results achieved thus far do, however,
provide valuable insight into the pathophysiology of CAD and MI
and are starting points for individualized treatment strategies.
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